Product Description
Zhengda Tianqing Pharmaceutical Group/Sailing Pharmaceutical Technology/Zhengda Tianqing Pharmaceutical Group is developing tq-b3234, an Oral MEK1 Inhibitor,MEK2 Inhibitor for Advanced Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02996838)
Mechanisms of Action: MEK1 Inhibitor, MEK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location:
Company Founding Year: 1997
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Neurofibroma, Plexiform
Phase 1: Neurofibroma|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20212106 |
CTR20212106 | P1 |
Completed |
Neurofibroma |
2026-01-15 |
2026-01-25 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07407803 |
TQ-B3234-III-01 | P3 |
Not yet recruiting |
Neurofibroma, Plexiform |
2027-12-01 |
10% |
2026-02-13 |
Primary Endpoints |
CTR20170224 |
CTR20170224 | P1 |
Recruiting |
Oncology Unspecified |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|